SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1726)12/14/2006 11:39:54 AM
From: tuck  Respond to of 1826
 
OK, point taken, but if it flopped, would the stock have gone up?

25 to 50 million actually matters to MOGN.

Cheers, Tuck



To: tom pope who wrote (1726)12/14/2006 6:32:36 PM
From: exixi  Read Replies (2) | Respond to of 1826
 
Only $25 to $50 million??

Where is Eric pulling that figure from? MGI has reiterated a $200 to $250 million market during their last presentation at Lazard.

Hospitals and clinics will get more money for outpatient reimbursement if they choose the better performing Aloxi.

Eric, look at the CINV data and you will see Aloxi is superior to Zofran. Which would you want if you had a choice?

Has Merrill reiterated their $25 target??


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News